Medicarpin

Medicarpin at a Glance

Medicarpin is the best-known pterocarpan — a small, tricyclic isoflavonoid that legumes make as a phytoalexin, an antimicrobial compound synthesised on demand when the plant is infected or wounded. It is the signature chemical-defence molecule of the pea and bean family (Fabaceae), notably alfalfa, red clover, astragalus, chickpea and peanut, and its native job is antifungal ^{12,25Reference 12Li ZS et al. · 1997Vacuolar uptake of the phytoalexin medicarpin by the glutathione conjugate pumpView study →Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}.

Biosynthetically it sits at the end of the isoflavonoid → pterocarpan branch, built downstream of the isoflavone formononetin (itself the 4′-O-methyl ether of daidzein) ^{13,23Reference 13Guo L · 1995Molecular cloning and expression of alfalfa (Medicago sativa L.) vestitone reductase, the penultimate enzyme in medicarpin biosynthesisView study →Reference 23Guo L et al. · 1994Conversion of vestitone to medicarpin in alfalfa (Medicago sativa L.) is catalyzed by two independent enzymesView study →}. Its methylenedioxy sibling maackiain is the equivalent phytoalexin of chickpea and other legumes.

The reason medicarpin has drawn pharmacological attention is a genuinely interesting osteogenic signal: in rodent models it both stimulates bone-forming osteoblasts and suppresses bone-resorbing osteoclasts, conserving bone in ovariectomised (oestrogen-deficient) animals without the uterine effects of oestrogen ^{1,2Reference 1Bhargavan B et al. · 2012AnimalMedicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic actionView study →Reference 2Tyagi AM et al. · 2010AnimalMedicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized miceView study →}. Alongside this it shows preclinical anticancer, anti-inflammatory and neuroprotective activity. The honest headline, though, is that every therapeutic finding is preclinical — rodent or in vitro — with no human trials, and much of the work comes from a single research programme. Its oral bioavailability is also modest, which tempers the in-vitro numbers.

The Isoflavonoid → Pterocarpan Branch

The compound-unique angle of medicarpin is where it comes from. Most isoflavonoids here — genistein, daidzein, formononetin, biochanin A — are isoflavones, flat molecules with a single extra ring. Pterocarpans are the next step: the isoflavone skeleton is reduced and cyclised into a rigid, four-ring cage, and that structural change turns a mild phyto-oestrogen into a dedicated antimicrobial.

The route to medicarpin is well mapped in alfalfa ^{13,14,23Reference 13Guo L · 1995Molecular cloning and expression of alfalfa (Medicago sativa L.) vestitone reductase, the penultimate enzyme in medicarpin biosynthesisView study →Reference 14Biala W et al. · 2017The Medicago truncatula ABCG10 transporter is involved in the transport of 4-coumarate and liquiritigenin, precursors in the medicarpin biosynthetic pathwayView study →Reference 23Guo L et al. · 1994Conversion of vestitone to medicarpin in alfalfa (Medicago sativa L.) is catalyzed by two independent enzymesView study →}:

• Formononetin (a 4′-methoxy isoflavone) is hydroxylated to 2′-hydroxyformononetin by a cytochrome-P450 isoflavone 2′-hydroxylase.
• Isoflavone reductase reduces it to vestitone.
• Vestitone reductase and DMI dehydratase (7,2′-dihydroxy-4′-methoxyisoflavanol dehydratase) then act in sequence — what was once mislabelled a single “pterocarpan synthase” is really these two independent enzymes — closing the ring to give (−)-medicarpin ^{23Reference 23Guo L et al. · 1994Conversion of vestitone to medicarpin in alfalfa (Medicago sativa L.) is catalyzed by two independent enzymesView study →}.

Because medicarpin is downstream of formononetin, the same legumes that are rich in isoflavones (alfalfa, red clover, astragalus) are the ones that produce medicarpin under stress. This is also why the molecule occurs almost exclusively as the single (6aR,11aR)-(−) enantiomer in plants — the enzymes are stereospecific ^{25Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}.

What It's Used For

Medicarpin’s therapeutic literature is preclinical and concentrated on bone, with a scattering of oncology, immunology and neuroscience studies layered on top of its native antifungal role. The load-bearing caveat runs through all of it: isolated-molecule data, mostly rodent or in vitro, no human trials.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. There are no human data for medicarpin, so every score is capped by design — read the per-row basis.

01Osteogenic / anti-osteoporoticPromising48%Multiple in-vivo rodent studies (osteoblast + osteoclast + defect healing), defined ERβ mechanism, PK ^{1,2,4,7Reference 1Bhargavan B et al. · 2012AnimalMedicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic actionView study →Reference 2Tyagi AM et al. · 2010AnimalMedicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized miceView study →Reference 4Dixit M et al. · 2015Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathwaysView study →Reference 7Taneja I et al. · 2015A validated LC-ESI-MS/MS method for bioanalytical determination of an osteogenic phytoalexin, medicarpin, and its application to pharmacokineticsView study →}

02Antifungal (native phytoalexin)Shaky34%The molecule’s native defence role; in-vitro MICs against plant/wood fungi ^{12,25Reference 12Li ZS et al. · 1997Vacuolar uptake of the phytoalexin medicarpin by the glutathione conjugate pumpView study →Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}

03Anti-inflammatory / immunomodulatoryShaky32%In-vivo rodent arthritis (TH17), T-cell senescence models ^{3,9Reference 3Mansoori MN et al. · 2020Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokinesView study →Reference 9Tyagi AM et al. · 2012AnimalPremature T cell senescence in Ovx mice is inhibited by repletion of estrogen and medicarpin (a plant derived isoflavonoid)View study →}

04Anticancer / pro-apoptoticShaky30%In-vitro apoptosis in leukemia + bladder cancer lines; multidrug-resistance reversal ^{5,10,11Reference 5Trivedi R et al. · 2014Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathwayView study →Reference 10Gatouillat G et al. · 2015Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cellsView study →Reference 11Chen Y et al. · 2023Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cellsView study →}

Mechanisms

The load-bearing point is the ERβ-selective, non-uterotrophic bone action: it is what makes the osteogenic signal interesting (bone benefit without oestrogenic uterine stimulation), and it is still only shown in rodents ^{1,2Reference 1Bhargavan B et al. · 2012AnimalMedicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic actionView study →Reference 2Tyagi AM et al. · 2010AnimalMedicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized miceView study →}.

Pharmacokinetics

Medicarpin’s PK is the reality check on its in-vitro potency. A validated LC-MS/MS study in rats found it is rapidly absorbed but has an oral bioavailability of only ~17.4% ^{7Reference 7Taneja I et al. · 2015A validated LC-ESI-MS/MS method for bioanalytical determination of an osteogenic phytoalexin, medicarpin, and its application to pharmacokineticsView study →}. Tissue-distribution and excretion work confirmed modest oral bioavailability with substantial accumulation in liver and bone marrow — convenient for a bone-targeted agent, but a real ceiling on systemic exposure ^{8Reference 8Taneja I et al. · 2020AnimalBioavailability, tissue distribution and excretion studies of a potential anti-osteoporotic agent, medicarpin, in female ratsView study →}. The molecule is a small (MW 270) lipophilic pterocarpan, consistent with its ready absorption and hepatic handling; in vitro it also inhibits hepatic mixed-function oxidase (cytochrome-P450) activity, a signal that at higher exposures it could interfere with drug metabolism ^{22Reference 22Friedman FK et al. · 1985AnimalSpecificity of medicarpin and related isoflavonoids in inhibition of rat hepatic mixed function oxidase activityView study →}. No human pharmacokinetic data exist.

Clinical Trials

There are no clinical trials of medicarpin in any indication. The entire therapeutic literature is preclinical: in-vivo rodent studies for bone and inflammation, and cell-line studies for cancer.

Last checked: July 2026.

Isolate vs. Plant Studies

Almost all of medicarpin’s therapeutic evidence is the isolated molecule, not a whole plant — which cuts both ways. On the plus side, the bone studies dosed purified medicarpin (and a synthetic analogue), so the osteogenic effect is attributable to the molecule itself rather than a plant matrix ^{1,2,4,21Reference 1Bhargavan B et al. · 2012AnimalMedicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic actionView study →Reference 2Tyagi AM et al. · 2010AnimalMedicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized miceView study →Reference 4Dixit M et al. · 2015Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathwaysView study →Reference 21Goel A et al. · 2015AnimalGoel A, et al. (2015). 9-Demethoxy-medicarpin promotes peak bone mass achievement and has bone conserving effect in ovariectomized mice. Molecular and Cellular Endocrinology. https://pubmed.ncbi.nlm.nih.gov/25957087/View study →}. On the minus side, medicarpin is an inducible, low-abundance phytoalexin: an unstressed alfalfa or clover plant contains only ~1–2 µg per gram of fresh tissue ^{25Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}, so eating the herb delivers a negligible dose compared with the research injections and gavage. There is no whole-plant human trial that isolates a medicarpin effect, and the isoflavone-rich legumes it occurs in (alfalfa, red clover, astragalus) carry many other actives. The correct framing is: clean isolate mechanism in rodents, but the plant is not a practical delivery vehicle for the doses studied.

Its Role in Plants

In the legume, medicarpin is not a passive metabolite but an active defence compound. It is the archetypal phytoalexin — barely present in healthy tissue and synthesised rapidly when the plant detects a fungal pathogen, a wound, or a chemical elicitor ^{23Reference 23Guo L et al. · 1994Conversion of vestitone to medicarpin in alfalfa (Medicago sativa L.) is catalyzed by two independent enzymesView study →}. Elicitor treatment of alfalfa cells switches on the whole biosynthetic cascade within hours, with vestitone-reductase transcript rising before the enzyme activity and medicarpin accumulation that follow ^{13Reference 13Guo L · 1995Molecular cloning and expression of alfalfa (Medicago sativa L.) vestitone reductase, the penultimate enzyme in medicarpin biosynthesisView study →}.

Because medicarpin is toxic to the plant that makes it as well as to the fungus, the cell manages it carefully: it is conjugated (glucosylated and malonylated) for storage — in chickpea, medicarpin and maackiain accumulate as 3-O-glucoside-6′-O-malonate conjugates ^{24Reference 24Weidemann C et al. · 1991Medicarpin and maackiain 3-O-glucoside-6′-O-malonate conjugates are constitutive compounds in chickpea (Cicer arietinum L.) cell culturesView study →} — and the free aglycone is pumped into the vacuole by a glutathione-conjugate transporter ^{12Reference 12Li ZS et al. · 1997Vacuolar uptake of the phytoalexin medicarpin by the glutathione conjugate pumpView study →}. A dedicated membrane transporter, ABCG10, moves precursors along the pathway in Medicago truncatula ^{14Reference 14Biala W et al. · 2017The Medicago truncatula ABCG10 transporter is involved in the transport of 4-coumarate and liquiritigenin, precursors in the medicarpin biosynthetic pathwayView study →}. These are plant-biology functions and do not predict human pharmacology.

Prevalence in Nature

Medicarpin occurs across the legume family (Fabaceae), where it is the dominant pterocarpan phytoalexin, and it turns up in a few non-legume sources too. Its defining feature is that concentrations are inducible and highly variable: low in healthy tissue, high after stress.

Reported occurrences and levels:

• Alfalfa (Medicago sativa) — the namesake source; ~1–2 µg/g fresh weight in unstressed leaflets, far higher in elicited cell cultures ^{8,25Reference 8Taneja I et al. · 2020AnimalBioavailability, tissue distribution and excretion studies of a potential anti-osteoporotic agent, medicarpin, in female ratsView study →Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}.
• White clover (Trifolium repens) — ~1–2 µg/g fresh weight in leaflets ^{25Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}.
• Red clover (Trifolium pratense) and astragalus (Astragalus membranaceus) — as an isoflavonoid-pathway product of these isoflavone-rich legumes.
• Chickpea (Cicer arietinum) — accumulated (with maackiain) as glucoside-malonate conjugates in elicited cell cultures ^{24Reference 24Weidemann C et al. · 1991Medicarpin and maackiain 3-O-glucoside-6′-O-malonate conjugates are constitutive compounds in chickpea (Cicer arietinum L.) cell culturesView study →}.
• Peanut / groundnut (Arachis hypogaea) — from ~15 µg/g up to several mg/g in stressed tissue over time ^{25Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}.
• Non-legume sources — Dalbergia rosewoods and, notably, Brazilian red propolis, where medicarpin is a major constituent ^{17,25Reference 17Williams KP et al. · 2021Antigonococcal activity of (+)-medicarpinView study →Reference 25Tanimoto et al. · 2025ReviewA comprehensive review of medicarpin: a phytoalexin with therapeutic potentialView study →}.

Because it is a phytoalexin rather than a stored secondary metabolite, no single “abundance” figure is meaningful — the number depends entirely on how stressed the plant is.

Discovery & Synthesis

Medicarpin was characterised as the principal pterocarpan phytoalexin of alfalfa (Medicago sativa), and its name derives directly from that genus, Medicago. Interest in it grew through the 1980s and 1990s as the archetype for studying how legumes build pterocarpan defences, and its biosynthetic pathway from formononetin was worked out in alfalfa — the cloning of vestitone reductase (the penultimate enzyme) and the demonstration that vestitone-to-medicarpin conversion needs two independent enzymes were landmark steps ^{13,23Reference 13Guo L · 1995Molecular cloning and expression of alfalfa (Medicago sativa L.) vestitone reductase, the penultimate enzyme in medicarpin biosynthesisView study →Reference 23Guo L et al. · 1994Conversion of vestitone to medicarpin in alfalfa (Medicago sativa L.) is catalyzed by two independent enzymesView study →}.

The molecule occurs naturally as the single (6aR,11aR)-(−) enantiomer. Total syntheses of both enantiomers were later achieved: a unified synthesis of (−)-medicarpin (with related pterocarpans) using quinone-methide chemistry in 2015 ^{16Reference 16Feng J et al. · 2015Unified total syntheses of (−)-medicarpin, (−)-sophoracarpan A, and (±)-kushecarpin A with some structural revisionsView study →}, and an asymmetric total synthesis of (+)-medicarpin in 2017 ^{18Reference 18Yang X et al. · 2017Total synthesis of (+)-medicarpinView study →}. Manufacture today is not industrial — medicarpin is a research compound obtained by extraction from elicited plant material or by total/asymmetric synthesis for laboratory study, not a commercial supplement ingredient.

Patents: not yet researched.

Toxicity & Safety

Medicarpin carries a low toxicity flag, but that rating rests on thin, mostly indirect evidence — there is no dedicated toxicology package for the isolated molecule in humans, and its therapeutic doses are known only from rodents. The rating reflects the absence of red flags rather than a clean safety file.

Safety at a Glance

✅ Low / no toxicity

• No reported human toxicity, and low acute concern. The available zebrafish and rodent work shows no behavioural or physiological toxicity at studied doses; the rodent bone studies used the isolate without reported adverse effects ^{1,2Reference 1Bhargavan B et al. · 2012AnimalMedicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic actionView study →Reference 2Tyagi AM et al. · 2010AnimalMedicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized miceView study →}.
• Preclinical-only, and largely from one research programme. There are no human safety data at all, and much of the therapeutic record traces to a single laboratory — do not read the rodent doses as human-safe.
• Possible drug-metabolism interference. Medicarpin inhibits hepatic cytochrome-P450 (mixed-function oxidase) activity in vitro, a theoretical interaction signal for co-administered drugs that has not been characterised in humans ^{22Reference 22Friedman FK et al. · 1985AnimalSpecificity of medicarpin and related isoflavonoids in inhibition of rat hepatic mixed function oxidase activityView study →}.
• Isoflavonoid-family, oestrogen-receptor-active. It activates oestrogen receptor β (though not the uterotrophic ER-α); ER-modulating activity warrants caution pending human data, even though the rodent studies found no uterine effect ^{1Reference 1Bhargavan B et al. · 2012AnimalMedicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic actionView study →}.

Medicarpin is a phytoalexin the plant makes to be toxic to fungi, and it is toxic enough that the plant sequesters it into the vacuole to protect itself ^{12Reference 12Li ZS et al. · 1997Vacuolar uptake of the phytoalexin medicarpin by the glutathione conjugate pumpView study →} — a reminder that “plant defence compound” and “safe in humans” are separate questions. No reproductive or developmental toxicology exists for the isolated molecule; because medicarpin is oestrogen-receptor-active, that gap is worth flagging, but any pregnancy/lactation decision belongs on a herb or product page, not on this molecule page.

Dosage

There is no established or recommended human dose for medicarpin. It is a preclinical research compound, not a marketed supplement, and every dose figure in the literature is a rodent research dose — for example, the osteoporosis studies dosed rats and mice by oral gavage or injection at levels chosen for the experiment, not scaled to humans ^{1,2,4Reference 1Bhargavan B et al. · 2012AnimalMedicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic actionView study →Reference 2Tyagi AM et al. · 2010AnimalMedicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized miceView study →Reference 4Dixit M et al. · 2015Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathwaysView study →}. Given the molecule’s ~17% oral bioavailability ^{7Reference 7Taneja I et al. · 2015A validated LC-ESI-MS/MS method for bioanalytical determination of an osteogenic phytoalexin, medicarpin, and its application to pharmacokineticsView study →}, those figures do not translate to a human intake.

Dietary exposure from eating legumes is negligible relative to the studied doses, because medicarpin is a low-abundance, inducible phytoalexin (~1–2 µg/g in unstressed alfalfa/clover) rather than a stored constituent. These are research figures, not a personal recommendation.

References

1. Bhargavan B, et al. (2012). Medicarpin, a legume phytoalexin, stimulates osteoblast differentiation and promotes peak bone mass achievement in rats: evidence for estrogen receptor beta-mediated osteogenic action. Journal of Nutritional Biochemistry. https://pubmed.ncbi.nlm.nih.gov/21333515/
2. Tyagi AM, et al. (2010). Medicarpin inhibits osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice. Molecular and Cellular Endocrinology. https://pubmed.ncbi.nlm.nih.gov/20570709/
3. Mansoori MN, et al. (2020). Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. International Immunopharmacology. https://pubmed.ncbi.nlm.nih.gov/32097846/
4. Dixit M, et al. (2015). Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways. PLoS One. https://pubmed.ncbi.nlm.nih.gov/26657206/
5. Trivedi R, et al. (2014). Medicarpin, a legume phytoalexin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway. Cell Death & Disease. https://pubmed.ncbi.nlm.nih.gov/25321472/
6. Li Y, et al. (2022). Medicarpin improves depressive-like behaviors in a chronic unpredictable mild stress-induced mouse model of depression by upregulating liver X receptor β expression in the amygdala. Neurotoxicity Research. https://pubmed.ncbi.nlm.nih.gov/36445678/
7. Taneja I, et al. (2015). A validated LC-ESI-MS/MS method for bioanalytical determination of an osteogenic phytoalexin, medicarpin, and its application to pharmacokinetics. Journal of Chromatography B. https://pubmed.ncbi.nlm.nih.gov/26241182/
8. Taneja I, et al. (2020). Bioavailability, tissue distribution and excretion studies of a potential anti-osteoporotic agent, medicarpin, in female rats. Journal of Pharmaceutical and Biomedical Analysis. https://pubmed.ncbi.nlm.nih.gov/31855725/
9. Tyagi AM, et al. (2012). Premature T cell senescence in Ovx mice is inhibited by repletion of estrogen and medicarpin (a plant derived isoflavonoid). Osteoporosis International. https://pubmed.ncbi.nlm.nih.gov/21562872/
10. Gatouillat G, et al. (2015). Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/26598918/
11. Chen Y, et al. (2023). Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells. Acta Pharmaceutica. https://pubmed.ncbi.nlm.nih.gov/37307373/
12. Li ZS, et al. (1997). Vacuolar uptake of the phytoalexin medicarpin by the glutathione conjugate pump. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/9195760/
13. Guo L, Paiva NL (1995). Molecular cloning and expression of alfalfa (Medicago sativa L.) vestitone reductase, the penultimate enzyme in medicarpin biosynthesis. Archives of Biochemistry and Biophysics. https://pubmed.ncbi.nlm.nih.gov/7625843/
14. Biala W, et al. (2017). The Medicago truncatula ABCG10 transporter is involved in the transport of 4-coumarate and liquiritigenin, precursors in the medicarpin biosynthetic pathway. Journal of Experimental Botany. https://pubmed.ncbi.nlm.nih.gov/28369642/
15. Kureel J, et al. (2016). Identification of GRP78 as a molecular target of medicarpin in osteoblast cells by proteomics. Molecular and Cellular Biochemistry. https://pubmed.ncbi.nlm.nih.gov/27316719/
16. Feng J, et al. (2015). Unified total syntheses of (−)-medicarpin, (−)-sophoracarpan A, and (±)-kushecarpin A with some structural revisions. Angewandte Chemie International Edition. https://pubmed.ncbi.nlm.nih.gov/25476784/
17. Williams KP, et al. (2021). Antigonococcal activity of (+)-medicarpin. ACS Omega. https://pubmed.ncbi.nlm.nih.gov/34151106/
18. Yang X, et al. (2017). Total synthesis of (+)-medicarpin. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/29164880/
19. Li W, et al. (2021). A systems pharmacology approach uncovers the therapeutic mechanism of medicarpin against scopolamine-induced memory loss. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/34333326/
20. Imran KM, et al. (2018). Medicarpin induces lipolysis via activation of Protein Kinase A in brown adipocytes. BMB Reports. https://pubmed.ncbi.nlm.nih.gov/29353597/
21. Goel A, et al. (2015). 9-Demethoxy-medicarpin promotes peak bone mass achievement and has bone conserving effect in ovariectomized mice. Molecular and Cellular Endocrinology. https://pubmed.ncbi.nlm.nih.gov/25957087/
22. Friedman FK, et al. (1985). Specificity of medicarpin and related isoflavonoids in inhibition of rat hepatic mixed function oxidase activity. Pharmacology. https://pubmed.ncbi.nlm.nih.gov/3877941/
23. Guo L, et al. (1994). Conversion of vestitone to medicarpin in alfalfa (Medicago sativa L.) is catalyzed by two independent enzymes. Journal of Biological Chemistry. https://pubmed.ncbi.nlm.nih.gov/8071365/
24. Weidemann C, et al. (1991). Medicarpin and maackiain 3-O-glucoside-6′-O-malonate conjugates are constitutive compounds in chickpea (Cicer arietinum L.) cell cultures. Plant Cell Reports. https://pubmed.ncbi.nlm.nih.gov/24221677/
25. Tanimoto, de Miranda, Aldana-Mejía, et al. (2025). A comprehensive review of medicarpin: a phytoalexin with therapeutic potential. ACS Omega. https://doi.org/10.1021/acsomega.5c08170

View all 25 references▾